{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:51:33Z","timestamp":1791661893811,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Nationale Contre Le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006431","name":"Canc\u00e9rop\u00f4le Ile de France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008017","name":"Institut Gustave-Roussy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008017","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-25\\u201301"],"award-info":[{"award-number":["ANR-10-LABX-25\\u201301"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007241","name":"Universit\u00e9 Paris-Saclay","doi-asserted-by":"publisher","award":["165236"],"award-info":[{"award-number":["165236"]}],"id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.biopha.2022.113546","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T07:13:15Z","timestamp":1660806795000},"page":"113546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["NA1\u2014115\u20147, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes"],"prefix":"10.1016","volume":"154","author":[{"given":"Florian","family":"Daressy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"S\u00e9guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00ebtitia","family":"Favre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Corvaisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Apel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Groo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Litaudon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Dumontet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Malzert-Fr\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Desrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Roussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Wiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113546_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2022.113546_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2022.113546_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/cdd.2017.179","article-title":"MOMP, cell suicide as a BCL-2 family business","volume":"25","author":"Kalkavan","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2022.113546_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2022.113546_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cdd.2017.161","article-title":"The BCL-2 arbiters of apoptosis and their growing role as cancer targets","volume":"25","author":"Adams","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.biopha.2022.113546_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/biom10081109","article-title":"Targeting of BCL-2 family members during anticancer treatment: a necessary compromise between individual cell and ecosystemic responses","volume":"10","author":"Barill\u00e9-Nion","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2022.113546_bib7","article-title":"Inhibition of anti-apoptotic Bcl-2 proteins in preclinical and clinical studies: current overview in cancer","volume":"9","author":"D'Aguanno","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2022.113546_bib8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-mimetic drugs: blazing the trail for new cancer medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2022.113546_bib9","doi-asserted-by":"crossref","first-page":"70000","DOI":"10.18632\/oncotarget.12132","article-title":"Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells","volume":"7","author":"Bodo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.113546_bib10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2022.113546_bib11","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/0008-5472.CAN-06-2203","article-title":"Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737","volume":"67","author":"Tahir","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2022.113546_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2022.113546_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1541-7786.MCR-16-0280-T","article-title":"Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2\/Bcl-xL Blockade","volume":"15","author":"Williams","year":"2017","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.biopha.2022.113546_bib14","article-title":"Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199), Blood","volume":"5","author":"Phillips","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.biopha.2022.113546_bib15","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113546_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature09779","article-title":"Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7","volume":"471","author":"Wertz","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113546_bib17","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.2147\/OTT.S194549","article-title":"Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia","volume":"12","author":"Li","year":"2019","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.biopha.2022.113546_bib18","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1523\/JNEUROSCI.4940-07.2008","article-title":"Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage","volume":"28","author":"Arbour","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.113546_bib19","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2006-03-013771","article-title":"The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages","volume":"109","author":"Dzhagalov","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113546_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nature02067","article-title":"Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1","volume":"426","author":"Opferman","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113546_bib21","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1101\/gad.215871.113","article-title":"Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure","volume":"27","author":"Thomas","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2022.113546_bib22","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1126\/science.1191793","article-title":"Mcl-1 is essential for germinal center formation and B cell memory","volume":"330","author":"Vikstrom","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.113546_bib23","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","article-title":"MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2","volume":"90","author":"Kozopas","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2022.113546_bib24","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1128\/MCB.25.8.3117-3126.2005","article-title":"Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP","volume":"25","author":"Liu","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2022.113546_bib25","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/ng.2760","article-title":"Pan-cancer patterns of somatic copy number alteration","volume":"45","author":"Zack","year":"2013","journal-title":"Nat. Genet"},{"key":"10.1016\/j.biopha.2022.113546_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2022.113546_bib27","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2012-06-440230","article-title":"Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia","volume":"122","author":"Koss","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2022.113546_bib28","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/leu.2012.367","article-title":"MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma","volume":"27","author":"Wenzel","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2022.113546_bib29","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Wuill\u00e8me-Toumi","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2022.113546_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.43","article-title":"Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis","volume":"7","author":"Grabow","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2022.113546_bib31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1101\/gad.232009.113","article-title":"Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53","volume":"28","author":"Kelly","year":"2014","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2022.113546_bib32","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Disco"},{"key":"10.1016\/j.biopha.2022.113546_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.113546_bib34","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Disco"},{"key":"10.1016\/j.biopha.2022.113546_bib35","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113546_bib36","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-983","article-title":"Preclinical characterization of PRT1419, a potent, selective and orally available inhibitor of MCL1 (Abstract 983)","volume":"81","author":"Bhagwat","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2022.113546_bib37","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1158\/1538-7445.AM2020-6218","article-title":"Discovery and preclinical evaluation of AMG 397, a potent, selective and orally bioavailable MCL1 inhibitor","volume":"80","author":"Caenepeel","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2022.113546_bib38","doi-asserted-by":"crossref","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","article-title":"Discovery of S64315, a potent and selective Mcl-1 inhibitor","volume":"63","author":"Szlavik","year":"2020","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2022.113546_bib39","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ijbiomac.2021.07.166","article-title":"Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy","volume":"187","author":"Mittal","year":"2021","journal-title":"Int J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2022.113546_bib40","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/cmdc.202100011","article-title":"Drimane derivatives as the first examples of covalent bh3 mimetics that target MCL-1","volume":"16","author":"Daressy","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.biopha.2022.113546_bib41","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.phytochem.2009.01.012","article-title":"Cytotoxic sesquiterpenoids from Winteraceae of Caledonian rainforest","volume":"70","author":"Allouche","year":"2009","journal-title":"Phytochemistry"},{"key":"10.1016\/j.biopha.2022.113546_bib42","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1002\/1878-0261.12759","article-title":"The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders","volume":"14","author":"Robert","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.biopha.2022.113546_bib43","doi-asserted-by":"crossref","first-page":"45200","DOI":"10.1074\/jbc.M303868200","article-title":"Two distinct Gb3\/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3\/CD77 mAb and verotoxin-1","volume":"278","author":"Tetaud","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113546_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cellsig.2009.10.018","article-title":"Caspase-8-mediated cleavage of Bid and protein phosphatase 2A-mediated activation of Bax are necessary for Verotoxin-1-induced apoptosis in Burkitt's lymphoma cells","volume":"22","author":"Garibal","year":"2010","journal-title":"Cell Signal"},{"key":"10.1016\/j.biopha.2022.113546_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101626","article-title":"Active targeted nanoemulsions for repurposing of tegaserod in Alzheimer's disease treatment","volume":"13","author":"Seguy","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2022.113546_bib46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.15252\/embj.201488806","article-title":"Differential retrotranslocation of mitochondrial Bax and Bak","volume":"34","author":"Todt","year":"2015","journal-title":"Embo J."},{"key":"10.1016\/j.biopha.2022.113546_bib47","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.biopha.2018.04.103","article-title":"Antiproliferative and toxicological properties of drimanes obtained from Drimys brasiliensis stem barks","volume":"103","author":"Fratoni","year":"2018","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2022.113546_bib48","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2022.113546_bib49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1535-7163.MCT-21-0511","article-title":"Anti-apoptotic MCL1 protein represents critical survival molecule for most burkitt lymphomas and BCL2-negative diffuse Large B-cell Lymphomas","volume":"21","author":"Klanova","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2022.113546_bib50","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.4161\/auto.26168","article-title":"MCL1 is critical for mitochondrial function and autophagy in the heart","volume":"9","author":"Thomas","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.biopha.2022.113546_bib51","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1101\/gad.1156903","article-title":"DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells","volume":"17","author":"Cuconati","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2022.113546_bib52","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins","volume":"19","author":"Willis","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2022.113546_bib53","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3324\/haematol.2019.220525","article-title":"Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma","volume":"105","author":"Smith","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2022.113546_bib54","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1074\/jbc.M707762200","article-title":"MCL-1 inhibits BAX in the absence of MCL-1\/BAX Interaction","volume":"283","author":"Germain","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.113546_bib55","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1101\/gad.276725.115","article-title":"Inactivation of prosurvival Bcl-2 proteins activates Bax\/Bak through the outer mitochondrial membrane","volume":"30","author":"O'Neill","year":"2016","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2022.113546_bib56","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nchembio.2174","article-title":"Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain","volume":"12","author":"Akcay","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2022.113546_bib57","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41419-020-2505-1","article-title":"Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX\/BAK hetero-complexes","volume":"11","author":"Seiller","year":"2020","journal-title":"Cell Death Dis."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222009350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222009350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:32:51Z","timestamp":1791660771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222009350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":57,"alternative-id":["S0753332222009350"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113546","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NA1\u2014115\u20147, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113546"}}